Introduction
============

It has been reported that thyroid carcinomas, the most frequently reported endocrine neoplasia, account for only 3%--4% in all human tumors, but the incidence of thyroid cancer is steadily increasing and has the highest increase in incidence within the past two decades.[@b1-ott-10-247] Currently, the use of neck ultrasonography is widely used in the diagnosis of thyroid cancer and brings light to the detection of many small early-stage tumors.[@b2-ott-10-247] However, the incidence of detection of large tumors and advanced stage tumor patients have also increased in these years.[@b3-ott-10-247],[@b4-ott-10-247] Thyroid cancer can be categorized into four histotypes: follicular thyroid carcinoma (FTC), papillary thyroid carcinoma (PTC), anaplastic thyroid carcinoma, and medullary thyroid carcinoma (MTC). PTC, the most common type of thyroid cancer, represents 80% of patients, followed by FTC (10%).[@b5-ott-10-247],[@b6-ott-10-247] PTC derives from the follicular cells of the thyroid, and it has a distinctive papillary architecture. In addition, the nuclear membrane of cells in PTC has several distinctive alternations, such as grooves, pseudoinclusions, and optical clearing. In contrast to the papillary carcinomas, in which the change of nuclear membrane alternations is vital, the diagnosis of FTC depends on whether the thyroid tumor has invaded through the surrounding vessels. MTC has a rare incidence accounting for \~3%, which derives from parafollicular C cells.[@b7-ott-10-247] Compared with FTC and PTC -- well differentiated cancer -- MTC has a more aggressive clinical characteristic.[@b8-ott-10-247] MTC often occurs in a form of inherited cancer, which is known as multiple endocrine neoplasia type 2.[@b9-ott-10-247] In recent decades, although many genetic studies for thyroid cancer have been performed, no specific biomarkers for the large number of sporadic thyroid cancers have been found.[@b10-ott-10-247]--[@b12-ott-10-247]

The Ras-associated domain family 1 (RASSF1) family of proteins, representing one type of Ras effectors, can inhibit the development of cancer. RASSF1A, one of the seven iso-forms of the RASSF1 family and located on 3p21, is the most common epigenetically inactivated tumor suppressor genes via promoter methylation in human cancers.[@b13-ott-10-247],[@b14-ott-10-247] It can bind Ras protein in a guanosine triphosphate-dependent manner to mediate the cell apoptotic, which has a similar function with Nore1 in mouse.[@b14-ott-10-247] In many solid tumors, RASSF1A, as a component of crucial cell signal pathways, plays an important role in the Ras/PI3K/AKT, Ras/RAF/MEK/ERK, and Hippo pathways, and the inactivation of RASSF1A can result in the alternations of clinical characteristic in tumors.[@b15-ott-10-247],[@b16-ott-10-247] It has been reported that the CpG methylation of RASSF1A promoter can lead to the loss-of-expression of RASSF1A.[@b14-ott-10-247] Previous studies have found that the RASSF1A promoter methylation can increase the risk of lung cancer, breast cancer, prostate cancer, ovarian cancer, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, and gastric cancer.[@b17-ott-10-247]--[@b24-ott-10-247] Furthermore, these results indicated that the RASSF1A promoter methylation may be a significant prognostic factor for many human cancers. Despite a number of studies performed on thyroid cancer patients, the relationship of RASSF1A promoter methylation with thyroid cancer risk and pathogenesis remains controversial. To clarify these controversial results, a meta-analysis was performed.

Methods
=======

Publication search
------------------

Relevant literature was retrieved from PubMed, Embase, ISI Web of Knowledge, and Chinese National Knowledge Infrastructure databases up until September 2016, without language restrictions. The following keywords were applied: "RASSF1 protein, human (Supplementary Concept)," "Thyroid Neoplasms (Mesh)," "Methylation (Mesh)," "RASSF1A," "thyroid cancer," and "hypermethylation" to search eligible studies. Review articles and the references from relevant primary studies were manually searched for identifying additional potential studies.

Inclusion and exclusion criteria
--------------------------------

The inclusion criteria were as follows: 1) studies primarily evaluating the frequency of RASSF1A promoter methylation in thyroid cancer with control group, 2) studies that have a case--control design, 3) studies that had sufficient data of frequency, and 4) patients who had been accurately diagnosed according to the diagnostic criteria. Studies were removed if they met one of the items: 1) reviews, meta-analysis, or animal studies; 2) duplicate data; and 3) study performed in the cell lines.

Data extraction
---------------

The following data were extracted from the eligible studies: year of publication, country, ethnicity, frequency of RASSF1A promoter methylation, cancer type, method of methylation detection, and sample type. The information was reviewed by two investigators. If the two investigators had divergence, the disagreement was resolved by consulting with the other authors.

Quality assessment
------------------

To ensure the high quality of included literatures, the Newcastle--Ottawa scale (NOS) table was applied to assess the methodological quality of observational studies. The NOS is commonly used in the quality assessment of nonrandomized studies, such as case--control and cohort studies. The scores of quality assessment range from 0 to 9. If the study got a score \<5 it was excluded.

Trial sequential analysis
-------------------------

In a cumulative meta-analysis, false-positive and false-negative results may arise, which result from the repeated testing and the adding of other studies. Therefore, it was crucial to lower the risk of type I error and type II error in the repeated statistics. In addition, interim analysis was performed to estimate the required sample size according to the data in the common trials and to avoid wasting of the sample. In this present meta-analysis, the trial sequential analysis was performed to estimate the required information size (RIS) and observe whether the result was conclusive through controlling the risk of type I error and type II error. TSA 0.9 software ([www.ctu.dk/tsa](http://www.ctu.dk/tsa)) was applied to conduct these analyses by combining the RIS with trial sequential monitoring boundaries. The trial sequential analysis was conducted at the level of 5% risk of type I error and 80% power of statistical test (5% risk of type II error). Moreover, adjusted information size was calculated with a relative risk reduction (−50%) according to the incidence of control and case groups.

Statistical analysis
--------------------

The frequency of RASSF1A promoter methylation in case and control groups was collected to calculate the pooled odds ratios (ORs) and 95% confidence interval (CI),[@b25-ott-10-247] evaluating the strength of association of RASSF1A promoter methylation with thyroid cancer risk or thyroid cancer clinical characteristics. Heterogeneity among studies was measured using Cochran's *Q*-test and Higgin's *I*^2^.[@b26-ott-10-247],[@b27-ott-10-247] If heterogeneity existed in studies (*P*\<0.05, *I*^2^\>50%), random-effects model was applied, otherwise, fixed-effects model was used (*P*\>0.05, *I*^2^\<50%).[@b28-ott-10-247],[@b29-ott-10-247] In addition, subgroup analysis based on ethnicity and sample type were conducted to detect the source of heterogeneity and lower the between-study heterogeneity. Begg's test and Egger' test were used to check for the publication bias. When the *P*-value was \<0.05, publication bias was considered as significant. The aggregated sensitivity and specificity were observed by conducting the sensitivity analysis. All meta-analyses were performed using Stata software 12.0 (Stata Corporation, College Station, TX, USA).

Results
=======

Characteristics of studies
--------------------------

Through searching PubMed, Embase, ISI Web of Knowledge, and Chinese National Knowledge Infrastructure databases, 25 publications were initially retrieved. Eight duplicate articles were removed. After reading titles and abstracts, four articles were excluded due to uncorrelated contents. Furthermore, full-text was read to eliminate irrelevant literatures, and two articles were eliminated because they had no sufficient data of RASSF1A promoter methylation. Finally, 10 publications with 422 patients and 219 controls were identified in this meta-analysis. Of these studies, seven studies were performed in Caucasians,[@b30-ott-10-247]--[@b36-ott-10-247] while three studies were conducted in Asians.[@b37-ott-10-247]--[@b39-ott-10-247] The detection of RASSF1A promoter methylation applied methylation-specific polymerase chain reaction and quantitative methylation-specific polymerase chain reaction. With regard to the type of control sample, normal tissue was used in five studies,[@b31-ott-10-247],[@b33-ott-10-247],[@b35-ott-10-247],[@b36-ott-10-247],[@b39-ott-10-247] four studies applied benign tissue,[@b31-ott-10-247],[@b32-ott-10-247],[@b35-ott-10-247],[@b38-ott-10-247] and adjacent tissue was applied in two studies[@b34-ott-10-247],[@b37-ott-10-247] ([Figure 1](#f1-ott-10-247){ref-type="fig"}; [Tables 1](#t1-ott-10-247){ref-type="table"} and [S1](#SD1-ott-10-247){ref-type="supplementary-material"}[](#SD2-ott-10-247){ref-type="supplementary-material"}[](#SD3-ott-10-247){ref-type="supplementary-material"}[](#SD4-ott-10-247){ref-type="supplementary-material"}[](#SD5-ott-10-247){ref-type="supplementary-material"}--[S6](#SD6-ott-10-247){ref-type="supplementary-material"}).

Quantitative data synthesis
---------------------------

According to this meta-analysis, there was a significant association of RASSF1A promoter methylation with thyroid cancer risk (OR=5.94, 95% CI=2.09--16.89, *P*\<0.05). When stratified by the ethnicity, a significant increased risk of thyroid cancer was detected in Asians, but not in Caucasians. In the stratified analysis by sample type, significantly increased risks were found in both normal tissues and adjacent tissues in detection of RASSF1A promoter methylation in thyroid cancer (normal tissue: OR=9.55, CI=4.21--21.67, *P*\<0.05; adjacent tissue: OR=6.80, CI=2.49--18.56, *P*\<0.05). Furthermore, significant association was also found in both FTC and PTC (for FTC: OR=11.88, CI=5.80--24.32, *P*\<0.05; for PTC: OR=8.07, CI=3.54--18.41, *P*\<0.05). In evaluating the association for pathological stage of thyroid cancer, no significant correlations of RASSF1A promoter methylation with distant metastasis and TNM-stage were observed ([Figures 2](#f2-ott-10-247){ref-type="fig"}[](#f3-ott-10-247){ref-type="fig"}--[4](#f4-ott-10-247){ref-type="fig"}; [Table 2](#t2-ott-10-247){ref-type="table"}).

Literature qualities
--------------------

In this meta-analysis, 10 studies were scored by NOS table by two independent authors. The scores of eligible literatures ranged from 6 to 8, suggesting that the quality of included studies were of a high quality and the inclusion criteria were satisfied. The detailed information is shown in [Table 1](#t1-ott-10-247){ref-type="table"}.

Publication bias and sensitivity analysis
-----------------------------------------

The results of Begg's test and Egger's test indicated that no significant publication bias existed in the analysis of association between RASSF1A promoter methylation and thyroid cancer risk or pathological characteristics. (For risk of thyroid: Begg's test *P*=0.453, Egger's test *P*=0.377; for distant metastasis: Begg's test *P*=0.624, Egger's test *P*=0.669; for TNM-stage: Begg's test *P*=0.117, Egger's test *P*=0.441). Sensitivity analysis indicated that the results were stable in this meta-analysis, and the pooled ORs did not have a significant change by omitting each study ([Figures 5](#f5-ott-10-247){ref-type="fig"}[](#f6-ott-10-247){ref-type="fig"}--[7](#f7-ott-10-247){ref-type="fig"}).

Trial sequential analysis
-------------------------

Trial sequential analysis indicated that *Z*-curve crossed the traditional boundary and the monitoring boundary for benefit, which indicated that no further studies were performed to study this association of RASSF1A promoter methylation with thyroid cancer risk. The *Z*-curve did not reach the boundary of RIS, and the RIS was 1,115. In other associations, no trial sequential analysis was conducted for the small number of samples ([Figure 8](#f8-ott-10-247){ref-type="fig"}).

Discussion
==========

Epigenetic alternations play an important role in the regulation of gene expression, especially in mammalian cells. DNA methylation usually occurs in CpG islands -- clusters of CpGs of gene promoter region, which can lead to gene activation or inactivation. The hypermethylation of gene promoter represses gene expression by inhibiting gene transcription and further affects the total cell signal pathway. The inactivation of RASSF1A, one of tumor suppressor genes, is critical in the tumorigenesis of thyroid cancer. The changes in gene structure, deletion, or mutation can result in the irreversible loss of RASSF1A function. Alternatively, the cumulative RASSF1A methylation can also influence the expression and affect the progression of cancers, such as tumor differentiation and metastasis. In previous studies of thyroid cancers, many genes methylation have a significant association with the development of thyroid tumor. For example, p16INK4A/CDKN2A, p21CIP1/CDKN1B, and p27KIP1/CDKN1B, considering as tumor suppressors, can regulate the activity of cyclin--CDK complexes in mammalian cells. However, the expression of these genes in which promoter methylation is detected in 30% of thyroid tumor was commonly downregulated in thyroid cancer patients.[@b40-ott-10-247],[@b41-ott-10-247] In addition, the hypermethylation of thyrotropin receptor gene, receptor, fibroblast growth factor type 2, and receptor, fibroblast growth factor type 1 existed in thyroid cancers.[@b42-ott-10-247]--[@b44-ott-10-247] RASSF1A protein, lacking enzymatic activity, contains a Ras-association domain and can regulate the cell cycle and apoptosis.[@b13-ott-10-247],[@b14-ott-10-247] Many studies have found that the RASSF1A promoter inactivation was frequent in thyroid cancers, \>30% of thyroid tumors,[@b33-ott-10-247],[@b34-ott-10-247],[@b37-ott-10-247],[@b39-ott-10-247] but other reports also observed that the RASSF1A promoter methylation did not have significant correlations with thyroid cancer risk.[@b31-ott-10-247],[@b35-ott-10-247],[@b36-ott-10-247] Thus, it is necessary to conduct a meta-analysis to determine the strength of association between RASSF1A promoter methylation and thyroid cancer. In the literature retrieval, a previous meta-analysis was found.[@b45-ott-10-247] However, the meta-analysis only explored the association between RASSF1A promoter methylation and PTC risk, and no clinical information was included. The result of the previous study indicated a significant association of RASSF1A promoter methylation with PTC risk. This was the same result in this meta-analysis. To discuss the association of RASSF1A promoter methylation with FTC risk, distant metastasis, and TNM-stage, the meta-analysis was conducted.

In this study, the results indicated that aberrant methylation of RASSF1A promoter was more frequently detected in thyroid cancer than in noncancerous controls. In the included studies, although the results of Wang et al[@b39-ott-10-247] and Qu et al[@b37-ott-10-247] demonstrated that the frequency of RASSF1A promoter methylation increased the risk of thyroid cancer, the pooled ORs and 95% CI show that there was a significant association between RASSF1A promoter methylation and the risk of thyroid cancer in Asians. Furthermore, a small degree of heterogeneity among studies was noticed in the overall analysis. Therefore, the stratified analysis, on the basis of sample type and ethnicity, was carried out to reduce the heterogeneity. At the same time, the pooled ORs indicated that the significant association was found in the stratified analysis based on ethnicity and sample type. Furthermore, between-study heterogeneity, to a large extent, disappeared in the subgroup analysis. This phenomenon indicated that the sample type and ethnicity were the primary cause of heterogeneity. Interestingly, no significant association between the frequency of RASSF1A promoter methylation in thyroid malignant tumor and the frequency in thyroid benign tumor existed. In other subgroups, the higher frequency of FTC and PTC group was found, compared with the nontumorous group. From all eligible studies in this meta-analysis, no results indicated that the RASSF1A promoter methylation had a significant influence in the metastasis of thyroid tumor.[@b30-ott-10-247],[@b36-ott-10-247]--[@b39-ott-10-247] In the meantime, the result of this statistical analysis was similar to the previous studies (for M0-stage and M1-stage: OR=1.18, 95% CI=0.64--2.16, *P*\<0.05). Moreover, no significant association between the frequency of RASSF1A methylation and TNM-stage of thyroid cancer (for I-stage and II--IV-stage: OR=1.79, 95% CI=0.72--4.44, *P*\<0.05) was found. In the included studies, one study found a significant association,[@b38-ott-10-247] but two studies obtained negative results.[@b30-ott-10-247],[@b38-ott-10-247] These results were inconsistent, but now, to a large extent, we could say that the frequency of RASSF1A promoter methylation might not be related with the TNM-stage of thyroid cancer. Certainly, the small sample size may limit the power of statistics. From the trial sequential analysis, although no studies were continuously performed to evaluate the association of RASSF1A promoter methylation with thyroid cancer risk, further studies, investigating the association between RASSF1A promoter methylation and thyroid cancer pathogenesis, were still needed to be carried out.

In this meta-analysis, the publication bias was not detected in the eligible studies. Begg's test, Egger's test, and funnel plot were performed, which indicated that the data did not have a considerable discrepancy among studies. Furthermore, consistent results were found in sensitivity analysis. However, several potential limitations must be emphasized in this study. First, with few included studies in this meta-analysis, the influence of small sample size of case and control cannot be ruled out. Second, the value of cut-off point of methylation cannot be achieved, thus the sensitivity and specificity of methylation about thyroid cancer risks cannot be determined. Third, the clinical information was so little that the analysis of association of RASSF1A promoter methylation with the pathogenesis of thyroid cancer patients cannot be performed.

Conclusion
==========

This meta-analysis showed that RASSF1A promoter methylation might play an important role in thyroid cancer initiation and progression. The RASSF1A promoter methylation might be a promising biomarker for the early diagnosis of thyroid cancer. In addition, RASSF1A promoter methylation was associated with the increased risk of distant metastasis and late TNM-stage of thyroid cancer patients. However, in consideration of the limitations acknowledged above, more large-scale, multicenter, and well-designed case--control or cohort researches will provide more insights into the role of RASSF1A promoter methylation in the risk and pathogenesis of thyroid cancer.

Supplementary materials
=======================

###### 

Thyroid cancer risk

  References                                Country                      Ethnicity   Histology                      U (n)   M (n)   U (n)   M (n)   Methods   Control type      NOS score
  ----------------------------------------- ---------------------------- ----------- ------------------------------ ------- ------- ------- ------- --------- ----------------- -----------
  Santoro et al[@b46-ott-10-247]            Italy                        Caucasian   Thyroid carcinoma              NR      NR      10      9       MSP       NR                NR
  Brait et al[@b47-ott-10-247]              USA                          Caucasian   Thyroid carcinoma              1       13      5       38      QMSP      Normal tissue     6
  Brait et al[@b47-ott-10-247]              USA                          Caucasian   Thyroid carcinoma              1       43      5       38      QMSP      Benign tissue     6
  Qu and Xue[@b48-ott-10-247]               People's Republic of China   Asian       Thyroid carcinoma              21      7       13      15      MSP       Adjacent tissue   8
  Dai et al[@b49-ott-10-247]                People's Republic of China   Asian       Thyroid carcinoma              22      10      20      30      MSP       Benign tissue     8
  Mohammadi[@b50-ott-10-247]                Iran                         Caucasian   Thyroid carcinoma              2       23      6       19      MSP       Benign tissue     7
  Wang et al[@b51-ott-10-247]               China                        Asian       Thyroid carcinoma              10      0       25      63      MSP       Normal tissue     6
  Lee et al[@b52-ott-10-247]                Sweden                       Caucasian   Follicular thyroid carcinoma   16      5       3       18      MSP       Normal tissue     7
  Nakamura et al[@b53-ott-10-247]           USA                          Caucasian   Thyroid carcinoma              27      0       51      27      MSP       Adjacent tissue   7
  Xing et al[@b54-ott-10-247]               USA                          Caucasian   Thyroid carcinoma              14      0       32      19      QMSP      Normal tissue     7
  Xing et al[@b54-ott-10-247]               USA                          Caucasian   Thyroid carcinoma              14      0       5       4       QMSP      Benign tissue     7
  Schagdarsurengin et al[@b55-ott-10-247]   Germany                      Caucasian   Thyroid carcinoma              3       1       11      27      MSP       Normal tissue     6
  **Normal and adjacent tissue**                                                                                                                                                
  Brait et al[@b47-ott-10-247]              USA                          Caucasian   Thyroid carcinoma              1       13      5       38      QMSP      Normal tissue     6
  Qu and Xue[@b48-ott-10-247]               People's Republic of China   Asian       Thyroid carcinoma              21      7       13      15      MSP       Adjacent tissue   8
  Wang et al[@b51-ott-10-247]               People's Republic of China   Asian       Thyroid carcinoma              10      0       25      63      MSP       Normal tissue     6
  Lee et al[@b52-ott-10-247]                Sweden                       Caucasian   Follicular thyroid carcinoma   16      5       3       18      MSP       Normal tissue     7
  Nakamura et al[@b53-ott-10-247]           USA                          Caucasian   Thyroid carcinoma              27      0       51      27      MSP       Adjacent tissue   7
  Xing et al[@b54-ott-10-247]               USA                          Caucasian   Thyroid carcinoma              14      0       32      19      QMSP      Normal tissue     7
  Schagdarsurengin et al[@b55-ott-10-247]   Germany                      Caucasian   Thyroid carcinoma              3       1       11      27      MSP       Normal tissue     6
  **Benign tissue**                                                                                                                                                             
  Brait et al[@b47-ott-10-247]              USA                          Caucasian   Thyroid carcinoma              1       43      5       38      QMSP      Benign tissue     6
  Dai et al[@b49-ott-10-247]                People's Republic of China   Asian       Thyroid carcinoma              22      10      20      30      MSP       Benign tissue     8
  Xing et al[@b54-ott-10-247]               USA                          Caucasian   Thyroid carcinoma              14      0       5       4       QMSP      Benign tissue     7
  Mohammadi et al[@b50-ott-10-247]          Iran                         Caucasian   Thyroid carcinoma              2       23      6       19      MSP       Benign tissue     7

**Abbreviations:** M, methylation sample; MSP, methylation-specific PCR; NOS, Newcastle--Ottawa scale; NR, not reported; PCR, polymerase chain reaction; QMSP, quantitative methylation-specific PCR; U, unmethylation sample.

###### 

Meta-analysis table

  Variables            Controls/cases (n)   OR      95% CI         *I*^2^ (%)   *P*-value
  -------------------- -------------------- ------- -------------- ------------ -----------
  **Heterogeneity**                                                             
  Total                136/365              5.94    2.09--16.89    55.40        0.028
  **Ethnicity**                                                                 
  Caucasian            98/249               5.4     1.40--20.86    59.60        0.03
  Asian                38/116               10.02   0.63--159.62   70.30        0.066
  **Disease type**                                                              
  FTC                  104/94               11.88   5.80--24.32    51.50        0.067
  PTC                  152/133              2.18    0.48--9.83     68.40        0.007
  **Sample type**                                                               
  Normal tissue        81/259               5.85    1.43--23.91    62.60        0.02
  Adjacent tissue      55/106               7.29    0.77--69.05    58.10        0.122
  **Pathogenesis**                                                              
  Distant metastasis   183/67               1.18    0.64--2.16     34.60        0.191
  TNM-stage            64/32                1.79    0.72--4.44     52.60        0.121

**Abbreviations:** CI, confidence interval; FTC, follicular thyroid carcinoma; OR, odds ratio; PTC, papillary thyroid cancer.

###### 

TNM-stage

  References                       Country                      Ethnicity   Histology           Thyroid tumor   Methods           
  -------------------------------- ---------------------------- ----------- ------------------- --------------- --------- --- --- -----
  Santoro et al[@b46-ott-10-247]   Italy                        Caucasian   Thyroid carcinoma   3               3         6   6   MSP
  Qu and Xue[@b47-ott-10-247]      People's Republic of China   Asian       Thyroid carcinoma   13              7         1   7   MSP
  Dai et al[@b49-ott-10-247]       People's Republic of China   Asian       Thyroid carcinoma   15              23        5   7   MSP

**Abbreviations:** M, methylation sample; MSP, methylation-specific PCR; PCR, polymerase chain reaction; U, unmethylation sample.

###### 

Distant metastasis

  References                                Country                      Ethnicity   Histology           Thyroid tumor   Methods             
  ----------------------------------------- ---------------------------- ----------- ------------------- --------------- --------- ---- ---- -----
  Santoro et al[@b46-ott-10-247]            Italy                        Caucasian   Thyroid carcinoma   6               8         3    1    MSP
  Qu and Xue[@b48-ott-10-247]               People's Republic of China   Asian       Thyroid carcinoma   11              8         3    6    MSP
  Dai et al[@b49-ott-10-247]                People's Republic of China   Asian       Thyroid carcinoma   16              27        4    3    MSP
  Wang et al[@b51-ott-10-247]               People's Republic of China   Asian       Thyroid carcinoma   30              43        3    13   MSP
  Schagdarsurengin et al[@b55-ott-10-247]   Germany                      Caucasian   Thyroid carcinoma   11              23        11   20   MSP

**Abbreviations:** M, methylation sample; MSP, methylation-specific PCR; PCR, polymerase chain reaction; U, unmethylation sample.

###### 

Papillary thyroid carcinoma

  References                                Country                      Ethnicity   Histology           Control   PTC   Methods        
  ----------------------------------------- ---------------------------- ----------- ------------------- --------- ----- --------- ---- ------
  Qu and Xue[@b48-ott-10-247]               People's Republic of China   Asian       Thyroid carcinoma   21        7     13        15   MSP
  Wang et al[@b51-ott-10-247]               People's Republic of China   Asian       Thyroid carcinoma   10        0     19        42   MSP
  Nakamura et al[@b53-ott-10-247]           USA                          Caucasian   Thyroid carcinoma   27        0     23        11   MSP
  Xing et al[@b54-ott-10-247]               USA                          Caucasian   Thyroid carcinoma   14        0     24        6    QMSP
  Schagdarsurengin et al[@b55-ott-10-247]   Germany                      Caucasian   Thyroid carcinoma   3         1     5         8    MSP

**Abbreviations:** M, methylation sample; MSP, methylation-specific PCR; PCR, polymerase chain reaction; PTC, papillary thyroid cancer; QMSP, quantitative methylation-specific PCR; U, unmethylation sample.

###### 

Follicular thyroid carcinoma

  References                                Country                      Ethnicity   Histology                      Control   FTC   Methods        
  ----------------------------------------- ---------------------------- ----------- ------------------------------ --------- ----- --------- ---- ------
  Qu and Xue[@b48-ott-10-247]               People's Republic of China   Asian       Thyroid carcinoma              21        7     13        15   MSP
  Lee et al[@b52-ott-10-247]                Sweden                       Caucasian   Follicular thyroid carcinoma   16        5     3         18   MSP
  Schagdarsurengin et al[@b55-ott-10-247]   Germany                      Caucasian   Thyroid carcinoma              3         1     3         7    MSP
  Xing et al[@b54-ott-10-247]               USA                          Caucasian   Thyroid carcinoma              3         9     14        0    QMSP
  Wang et al[@b51-ott-10-247]               People's Republic of China   Asian       Thyroid carcinoma              1         14    10        0    MSP
  Nakamura et al[@b53-ott-10-247]           USA                          Caucasian   Thyroid carcinoma              4         4     27        0    MSP

**Abbreviations:** FTC, follicular thyroid carcinoma; M, methylation sample; MSP, methylation-specific PCR; PCR, polymerase chain reaction; QMSP, quantitative methylation-specific PCR; U, unmethylation sample.
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![Trial sequential analysis comparing the Ras-associated domain family 1A promoter methylation frequency of control group and thyroid cancer group.\
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###### 

Characteristics of eligible studies in the meta-analysis

  References (year)                                Country                      Ethnicity   Histology   Control   Tumor   Methods   Control   QA score        
  ------------------------------------------------ ---------------------------- ----------- ----------- --------- ------- --------- --------- ---------- ---- ----
  Santoro et al[@b30-ott-10-247] (2013)            Italy                        Caucasian   TC          NR        NR      10        9         MSP        NR   NR
  Brait et al[@b31-ott-10-247] (2012)              USA                          Caucasian   TC          1         13      5         38        QMSP       NT   6
  Brait et al[@b31-ott-10-247] (2012)              USA                          Caucasian   TC          1         43      5         38        QMSP       BT   6
  Qu and Xue[@b37-ott-10-247] (2012)               People's Republic of China   Asian       TC          21        7       13        15        MSP        AT   8
  Dai et al[@b38-ott-10-247] (2011)                People's Republic of China   Asian       TC          22        10      20        30        MSP        BT   8
  Mohammadi et al[@b32-ott-10-247] (2011)          Iran                         Caucasian   TC          2         23      6         19        MSP        BT   7
  Wang et al[@b39-ott-10-247] (2009)               People's Republic of China   Asian       TC          10        0       25        63        MSP        NT   6
  Lee et al[@b33-ott-10-247] (2008)                Sweden                       Caucasian   FTC         16        5       3         18        MSP        NT   7
  Nakamura et al[@b34-ott-10-247] (2005)           USA                          Caucasian   TC          27        0       51        27        MSP        AT   7
  Xing et al[@b35-ott-10-247] (2004)               USA                          Caucasian   TC          14        0       32        19        QMSP       NT   7
  Xing et al[@b35-ott-10-247] (2004)               USA                          Caucasian   TC          14        0       5         4         QMSP       BT   7
  Schagdarsurengin et al[@b36-ott-10-247] (2002)   Germany                      Caucasian   TC          3         1       11        27        MSP        NT   6

**Abbreviations:** AT, adjacent tissue; BT, benign tissue; FTC, follicular thyroid carcinoma; M, methylation sample; MSP, methylation-specific PCR; NR, not reported; NT, normal tissue; PCR, polymerase chain reaction; QA, quality assessment; QMSP, quantitative methylation-specific PCR; TC, thyroid carcinoma; U, unmethylation sample.

###### 

Meta-analysis of association between Ras-associated domain family 1A promoter methylation and thyroid cancer risk

  Variables            Controls/cases (n)   OR      95% CI        Heterogeneity   
  -------------------- -------------------- ------- ------------- --------------- -------
  **Total**            118/347              8.27    4.38--15.62   47.20           0.078
  **Ethnicity**                                                                   
  Caucasian            80/231               9.25    3.97--21.56   46.90           0.110
  Asian                38/116               7.01    2.68--18.38   70.30           0.066
  **Disease type**                                                                
  FTC                  104/94               11.88   5.80--24.32   51.50           0.067
  PTC                  83/166               8.07    3.54--18.41   8.4             0.359
  **Sample type**                                                                 
  Normal tissue        63/241               9.55    4.21--21.67   51.80           0.081
  Adjacent tissue      55/106               6.80    2.49--18.56   58.10           0.122
  **Pathogenesis**                                                                
  Distant metastasis   183/67               1.18    0.64--2.16    34.60           0.191
  TNM-stage            64/32                1.79    0.72--4.44    52.60           0.121

**Abbreviations:** CI, confidence interval; FTC, follicular thyroid carcinoma; OR, odds ratio; PTC, papillary thyroid carcinoma.

[^1]: These authors contributed equally to this work
